ALT peer analysis
Altimmune (ALT) against its competitors: price, today's move, 1-year return and market value side by side.
ALT and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ABUS Arbutus Biopharma | $4.04 | 3.99% | -15.25% | $770.63M |
| ALGS Aligos Therapeutics | $2.16 | -15.95% | -62.67% | $16.06M |
| ASMB Assembly Biosciences | $19.95 | -10.82% | -29.97% | $457.30M |
| BMEA Biomea Fusion | $0.57 | -6.19% | -55.45% | $44.12M |
| ENTA Enanta Pharmaceuticals | $11.19 | -3.53% | 0.78% | $337.85M |
| GPCR Structure Therapeutics | $19.78 | -5.58% | -38.20% | $1.21B |
| INDP Indaptus Therapeutics | $3.21 | 10.69% | 15.54% | $328.40M |
| IVA Inventiva | $3.88 | -3.37% | 6.93% | $208.45M |
| MTVA MetaVia | $1.44 | -3.36% | -83.07% | $9.82M |
| VIR Vir Biotechnology | $10.30 | -21.55% | 144.41% | $2.25B |
| ALT Altimmune | $1.62 | -16.06% | -54.34% | $378.34M |
- ALT's peers: ABUS (Arbutus Biopharma), ALGS (Aligos Therapeutics), ASMB (Assembly Biosciences), BMEA (Biomea Fusion), ENTA (Enanta Pharmaceuticals), GPCR (Structure Therapeutics), INDP (Indaptus Therapeutics), IVA (Inventiva).
Updated 2026-11-13 04:50 UTC